- North America held the largest market share of 55% in 2023.
- Asia Pacific is expected to grow at the fastest rate during the forecast period.
- By type, the insulin patch pump segment accounted for the dominating share in 2023. The segment is observed to continue growth at a significant rate in the upcoming period.
- By component, the pod or patch segment held the largest share of the market in 2023.
- By end users, the hospitals segment held the largest share of the market in 2023.
The tubeless insulin pump market is experiencing significant growth driven by the rising prevalence of diabetes worldwide. Tubeless insulin pumps offer a convenient and discreet alternative to traditional insulin delivery methods, such as injections or tubed pumps, making them increasingly popular among diabetic patients. These pumps utilize advanced technology to deliver precise insulin doses continuously, mimicking the function of a healthy pancreas. The market is characterized by intense competition among key players, leading to continuous innovation and product development to cater to the evolving needs of diabetic individuals.
Get a Sample: https://www.precedenceresearch.com/sample/3944
Growth Factors:
Several factors contribute to the growth of the tubeless insulin pump market. Firstly, the increasing incidence of diabetes, fueled by sedentary lifestyles, unhealthy dietary habits, and aging populations, drives the demand for advanced insulin delivery systems. Tubeless pumps offer enhanced flexibility and ease of use compared to conventional methods, attracting a growing number of diabetic patients seeking improved management of their condition. Moreover, technological advancements, such as integrated continuous glucose monitoring (CGM) systems and smartphone connectivity, further enhance the appeal of tubeless insulin pumps, driving adoption rates among both patients and healthcare providers.
Tubeless Insulin Pump Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 19.25% |
| Global Market Size in 2023 | USD 2.05 Billion |
| Global Market Size by 2033 | USD 11.93 Billion |
| U.S. Market Size in 2023 | USD 790 Million |
| U.S. Market Size by 2033 | USD 4,590 Million |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type, By Component, and By End-users |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Tubeless Insulin Pump Market Dynamics
Drivers:
One of the primary drivers of the tubeless insulin pump market is the growing preference for non-invasive insulin delivery methods among diabetic individuals. Traditional insulin injections can be painful and inconvenient, leading many patients to seek alternative solutions such as tubeless pumps. Additionally, the increasing awareness about the benefits of maintaining tight glycemic control to prevent long-term complications of diabetes encourages patients to adopt advanced insulin delivery systems like tubeless pumps. Furthermore, the expanding reimbursement coverage for insulin pump therapy in many countries contributes to the market growth by reducing financial barriers to access for patients.
Restraints:
Despite its rapid growth, the tubeless insulin pump market faces certain restraints that may impede its full potential. One such restraint is the high initial cost associated with tubeless pump systems, which can be a barrier to adoption for some patients, particularly in developing regions with limited healthcare resources. Moreover, concerns about the reliability and accuracy of tubeless pump technology may deter healthcare providers and patients from fully embracing these devices. Additionally, regulatory hurdles and stringent approval processes for new insulin pump technologies pose challenges for market players looking to introduce innovative products.
Opportunity:
The tubeless insulin pump market presents numerous opportunities for growth and expansion in the coming years. With ongoing research and development efforts focused on improving the design, functionality, and reliability of tubeless pump systems, there is potential for the introduction of more advanced and user-friendly devices. Expansion into emerging markets with a high prevalence of diabetes, coupled with increasing healthcare expenditure and improving healthcare infrastructure, presents significant growth opportunities for market players. Furthermore, the integration of artificial intelligence and machine learning technologies into insulin pump systems holds promise for enhancing personalized diabetes management and optimizing insulin delivery algorithms.
Read Also: Protective Face Masks Market Size to USD 16.32 Bn by 2033
Region Insights:
The tubeless insulin pump market exhibits regional variations influenced by factors such as healthcare infrastructure, regulatory environment, and prevalence of diabetes. North America holds a significant share of the market, driven by high healthcare expenditure, favorable reimbursement policies, and a large diabetic population. Europe follows closely, characterized by a growing preference for technologically advanced medical devices and increasing awareness about diabetes management. The Asia Pacific region is poised for substantial growth due to rising disposable incomes, improving access to healthcare, and a burgeoning diabetic population. Latin America and the Middle East & Africa also present opportunities for market expansion, albeit with unique challenges related to healthcare accessibility and affordability.
Recent Developments
- In August 2023, the Tubeless insulin pump received FDA clearance for diabetes people. The Accu-Chek Solo micropump (Roche Diabetes) was granted 510(k) clearance from the FDA. Accu-Chek Solo micropump is tubeless, small, and lightweight. Users can place the device on four different infusion sites on the body. The device is detachable, allowing people with diabetes to change the infusion site when necessary.
- In July 2023, the FDA announced the clearance of Tandem Diabetes Care’s Mobi durable automated insulin pump. The approval covers people with diabetes aged six and above, expanding Tandem’s portfolio of products. Mobi features a 200-unit insulin cartridge and an on-pump button to provide an alternative to phone control for insulin boluses.
- In February 2024, Omnipod 5 received approval to integrate with the new freestyle libre two plus sensor. The Omnipod 5 hybrid closed loop system has received approval to integrate with the Abbott FreeStyle Libre 2 Plus Sensor in the UK, which will give people living with diabetes additional choice and flexibility for managing their blood sugar levels.
- In April 2023, Insulet announced FDA clearance of Omnipod GO, a first-of-its-kind basal-only insulin pod for people with type 2 diabetes aged 18 and above. Omnipod GO is a wearable, standalone insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Tubeless Insulin Pump Market Companies
- Medtronic plc
- Hoffmann-La Roche Ltd
- Tandem Diabetic Care, Inc.
- Insulet Corporation
- Ypsomed
- Cellenovo
- Abbott
- Tandem Diabetes Care
- Insulet Corporation
- Sooil Development
- Valeritas, Inc
- JingasuDelfu Co., Ltd.
- Cellnova
- Roche Holdings
- Spring Health Solutions
- Johnson & Johnson
- Medtrum Technologies
- Debiotech
- CeQur
- Valeritas Holding
- Animas Corporation
Segments Covered in the Report
By Type
- Insulin Patch Pump
- Traditional Pump
By Component
- Pod or Patch
- Remote
- Accessories
By End-users
- Hospitals
- Pharmacies
- E-commerce
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
